Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2020 Mar 10;11(10):942 Authors: Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM Abstract [This corrects the article DOI: 10.18632/oncotarget.4318.]. PMID: 32206190 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research